A newly proposed model suggests cancer cells may resist treatment not just through genetic mutations, but by dynamically reprogramming their gene activity. Credit: Shutterstock Cancer cells may “learn ...

Cancer immunology is advancing rapidly as researchers seek to unravel the complex, dynamic relationships between tumor cells, immune populations, and the ...

Kelonia is developing a next-gen blood cancer treatment that’ll reprogram T-cells to help patients’ immune systems fight ...

The role of neural hearing loss (NHL) in development of hearing impairment is increasingly recognised by the clinical community as central to hearing loss. -- NHL represents a significant unmet ...

Stress fiber–generated traction forces critically regulate mesenchymal stem cell (MSC) behavior, yet how mechanical cues are ...

Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases April 20, 2026 8:30 AM ...

By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...

Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus ...

Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer treatments.

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Objective Macrophages and kidney cell pyroptosis/ferroptosis could play an important role in the pathogenesis of lupus ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the ...